The Project “RA01: A revolutionary alternative to antibiotics to combat bacterial infectious diseases” is selected by CaixaImpulse Consolidate as one of the leading biomedical projects to
RemAb Therapeutics is one of the twenty Catalan technology startups supported by the Generalitat de Catalunya through the Startup Capital Programme of ACCIÓ. Learn more
RemAb Therapeutics has been awarded a Small and Medium-sized Enterprises (SME) instrument phase-1 Grant for our project of preventing hospital-acquired infections. This Grant is a part
RemAb Therapeutics was selected by Biocat to participate in “The Investment Readiness Series” in London, UK. On behalf of our Company, Dr. Bellowent to the Royal
RemAb Therapeutics has been selected to participate at the 23rd Healthcare Investment Forum of Barcelona (Col·legi de Metges de Barcelona). Dr. Rafael Mañez had the opportunity
Dr. Mañez, president and CMO of RemAb Therapeutics talked on September the 14th about the important role of Anti-αGal antibodies in infectious disease at “The challenge
RemAb Therapeutics been selected for presentation in the Investment Forum of BIOSPAIN 2018. It will also be an opportunity to introduce the company to national and
RemAb Therapeutics is one of the 15 companies all over Spain that have been chosen by EIT Health to receive founding from Headstart program to accelerate
RemAb Therapeutics attended the 15th Annual Anglonordic Life Science Conference in London last May. The main aim of RemAb Therapeutics was to introduce the company to
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy
